| Efficacy, Safety, and Pharmacokinetic Study of Prophylactic Emicizumab Versus No Prophylaxis in Hemophilia A Participants (NCT03315455) | Hoffmann-La Roche | 2018-04-26 |
| Open Label, Adaptive, Parallel Group PET Study Using RO7017773 And [11C] RO15-4513 (NCT03507569) | Hoffmann-La Roche | 2018-04-24 |
| A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) (NCT03456063) | Hoffmann-La Roche | 2018-04-24 |
| An Open-Label Crenezumab Study in Participants With Alzheimer's Disease (NCT03491150) | Hoffmann-La Roche | 2018-04-11 |
| A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck (NCT03452137) | Hoffmann-La Roche | 2018-04-03 |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer (NCT03424005) | Hoffmann-La Roche | 2018-03-30 |
| A Phase I Study of Etrolizumab Followed by Open-Label Extension and Safety Monitoring in Pediatric Patients With Moderate to Severe Ulcerative Colitis or Moderate to Severe Crohn's Disease (NCT03478956) | Hoffmann-La Roche | 2018-03-27 |
| A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (NCT03434379) | Hoffmann-La Roche | 2018-03-15 |
| A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NCT03369964) | Hoffmann-La Roche | 2018-03-14 |
| A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL (NCT03467373) | Hoffmann-La Roche | 2018-03-13 |
| A Study to Investigate the Pharmacokinetics, Safety, and Tolerability of Emicizumab in Healthy Chinese Volunteers (NCT03380780) | Hoffmann-La Roche | 2018-03-12 |
| Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic Leukemia (NCT03374137) | Hoffmann-La Roche | 2018-03-09 |
| A French Study to Evaluate the Usefulness of an Implantable Continuous Glucose Monitoring (CGM) Sensor to Improve Glycemic Control in Participants With Diabetes Mellitus (NCT03445065) | Hoffmann-La Roche | 2018-02-28 |
| A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera (NCT03287245) | Hoffmann-La Roche | 2018-02-21 |
| Basket Study to Evaluate the Therapeutic Activity of Simlukafusp Alfa as a Combination Therapy in Participants With Advanced and/or Metastatic Solid Tumors (NCT03386721) | Hoffmann-La Roche | 2018-02-19 |
| Study to Explore the Mechanism of Acquired Immune Escape In Participants With Metastatic Cancer Progressing on CPI Therapy (NCT03333655) | Hoffmann-La Roche | 2018-02-16 |
| Oral Immunomodulatory Tyrosine Kinase Inhibitor in Patients With Locally Advanced or Metastatic Solid Tumors (NCT03454243) | Hoffmann-La Roche | 2018-02-15 |
| A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer (NCT03800836) | Hoffmann-La Roche | 2018-02-13 |
| A Study of the Safety of Atezolizumab in Patients With Advanced or Metastatic Urothelial Carcinoma in Argentina (NCT03330886) | Hoffmann-La Roche | 2018-02-09 |
| A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (NCT03337724) | Hoffmann-La Roche | 2018-01-06 |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) (NCT03342053) | Hoffmann-La Roche | 2018-01-02 |
| A Study to Investigate The Effectiveness Of Atezolizumab In Patients With Inoperable Locally-Advanced Or Metastatic Urothelial Carcinoma Of The Urinary Tract (Announce) (NCT03399643) | Hoffmann-La Roche | 2017-12-28 |
| A Study of the Safety of Atezolizumab in Participants With Locally Advanced or Metastatic Non Small Cell Lung Cancer in Argentina (NCT03321695) | Hoffmann-La Roche | 2017-12-27 |
| A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) (NCT03337698) | Hoffmann-La Roche | 2017-12-27 |
| A Study to Characterize the Disease Behavior of Idiopathic Pulmonary Fibrosis (IPF) and Interstitial Lung Disease (ILD) During the Peri-Diagnostic Period (NCT03261037) | Hoffmann-La Roche | 2017-12-25 |
| A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer (NCT03280563) | Hoffmann-La Roche | 2017-12-22 |
| A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma (NCT03273153) | Hoffmann-La Roche | 2017-12-11 |
| A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) (NCT03232593) | Hoffmann-La Roche | 2017-11-29 |
| A Study to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Participants With Solid Tumors (NCT03362723) | Hoffmann-La Roche | 2017-11-27 |
| A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors (NCT03264066) | Hoffmann-La Roche | 2017-11-23 |
| A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps (NCT03280537) | Hoffmann-La Roche | 2017-11-21 |
| A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma (NCT03274492) | Hoffmann-La Roche | 2017-11-16 |
| A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitis With Nasal Polyps (NCT03280550) | Hoffmann-La Roche | 2017-11-15 |
| Evaluate the Effect of Entrectinib on the Pharmacokinetics of Midazolam in Cancer Patients (NCT03330990) | Hoffmann-La Roche | 2017-11-14 |
| A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma (NCT03312530) | Hoffmann-La Roche | 2017-11-13 |
| Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea (NCT03271554) | Hoffmann-La Roche | 2017-11-09 |
| A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer (NCT03292172) | Hoffmann-La Roche | 2017-11-08 |
| A Study of Bitopertin (RO4917838) in Adults With Non-Transfusion-Dependent (NTD) Beta-Thalassemia (NCT03271541) | Hoffmann-La Roche | 2017-10-26 |
| A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT03285763) | Hoffmann-La Roche | 2017-10-25 |
| An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA) (NCT03202368) | Hoffmann-La Roche | 2017-10-25 |
| Open-label Study to Assess the Effectiveness of Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis (IPF). (NCT03208933) | Hoffmann-La Roche | 2017-10-23 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension (NCT03293992) | Hoffmann-La Roche | 2017-10-10 |
| A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (NCT03178552) | Hoffmann-La Roche | 2017-09-22 |
| A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A) (NCT03148418) | Hoffmann-La Roche | 2017-09-20 |
| An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL) (NCT03289182) | Hoffmann-La Roche | 2017-09-15 |
| A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors (NCT03191799) | Hoffmann-La Roche | 2017-09-05 |